Avon Donates $20 Million to NCI for Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

BETHESDA, Maryland-The Avon Products Foundation has awarded $20 million to the National Cancer Institute to help support breast cancer research and expand early-phase clinical trials of promising techniques for prevention, diagnosis, and therapy.

BETHESDA, Maryland—The Avon Products Foundation has awarded $20 million to the National Cancer Institute to help support breast cancer research and expand early-phase clinical trials of promising techniques for prevention, diagnosis, and therapy.

The foundation also awarded $10 million each to the Massachusetts General Hospital/Harvard Comprehensive Cancer Center, the University of California, San Francisco Comprehensive Cancer Center, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. It said the funds would be used at each institution to support biomedical research, clinical care for medically underserved women, and construction of new facilities focusing on breast cancer research and care.

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Related Content